RECRUITING

Improving Medication Management in World Trade Center Responders

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

By 2030, the majority of World Trade Center (WTC) rescue and recovery workers (responders) will be aged 65 and over and at risk for aging-related conditions and consequences including the concurrent use of five or more medications (i.e., polypharmacy). The purpose of this research study is to investigate an educational approach targeting polypharmacy through de-prescribing unnecessary and burdensome medications via the support of informed discussions between WTC responders and their prescribing physicians.

Official Title

Promoting Healthy Aging Among WTC Responders: Frailty Trajectories And Intervention Strategies

Quick Facts

Study Start:2025-04-08
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07022990

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * A WTC responder already enrolled in the "Promoting Healthy Aging Among WTC Responders: Frailty Trajectories and Intervention Strategies" study cohort
  2. * aged 50 years or older, and
  3. * taking one of the five medication classes:
  4. * proton pump inhibitors (PPIs),
  5. * benzodiazepine (BZs) and
  6. * non-benzodiazepine sedative hypnotics ("Z-drugs"),
  7. * first-generation antihistamines (FGA), and
  8. * skeletal muscle relaxants (SMR).
  1. * None

Contacts and Locations

Study Contact

Patricia Kim
CONTACT
212-241-9370
patricia.kim@mssm.edu

Principal Investigator

Fred Ko, MD
PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai

Study Locations (Sites)

Icahn School of Medicine at Mount Sinai
New York, New York, 10029
United States

Collaborators and Investigators

Sponsor: Icahn School of Medicine at Mount Sinai

  • Fred Ko, MD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-08
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2025-04-08
Study Completion Date2026-06-30

Terms related to this study

Keywords Provided by Researchers

  • Deprescribe
  • Medication management

Additional Relevant MeSH Terms

  • Polypharmacy